Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma
Menée en France à partir de données portant sur 99 patients atteints d'un lymphome cutané à cellules T de stade avancé (âge : 18-70 ans ; durée médiane de suivi : 12,6 mois), cette étude prospective multicentrique évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité d'une greffe allogénique de cellules souches hématopoïétiques
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas, of which mycosis fungoides is the most common subtype that can eventually evolve into a leukaemia variant known as Sézary syndrome. 1 The clinical presentation of mycosis fungoides represents a broad spectrum, which ultimately guides prognosis and management. 2 Agar and colleagues 3 reported on the survival outcomes in patients with mycosis fungoides and Sézary syndrome. Although patients with stage IA–IIA disease have expected 5-year overall survival rates ranging from 78% to 94%, there is substantial impairment in outcomes upon disease progression to stage IIB or more advanced stages. Systemic therapies, including biologicals drugs or conventional chemotherapeutics, or both, are typically combined with skin-directed therapies in the management of advanced CTCL, but there is no known established standard of care; and these treatments have not yet affected the natural course of the disease
The Lancet , commentaire, 2022